Characterisation of vasodilatory responses in the presence of the CGRP receptor antibody erenumab in human isolated arteries.
Eloisa Rubio-BeltránAlejandro Labastida-RamírezKristian Agmund HaanesAntoon van den BogaerdtAd Jjc BogersClemens DirvenAh Jan DanserCen XuJosefin SnellmanAntoinette MaassenVanDenBrinkPublished in: Cephalalgia : an international journal of headache (2019)
Erenumab inhibits calcitonin gene-related peptide-induced vasodilatory responses in human middle meningeal arteries, human internal mammary arteries and human coronary arteries. Moreover, erenumab shows functional specificity as no interaction was observed with the relaxant responses to several vasodilators, nor the dihydroergotamine-dependent vasoconstrictor responses.